Georgia Cancer Info A Service of GeorgiaCORE     Admin Login  |  My Saved Results  |  Contact Us
Search the Website
Find Clinical Trials  |  About Clinical Trials  |  Glossary  |  Fast Facts  |  Eligibility  |  Phases  |  Sponsors  |  Types of Clinical Trials
HomeClinical TrialsA Phase 2, Open-Label Study Evaluating the Efficacy, Safety,...

Tell Us What You Think

In an effort to give you the best possible service, we would be grateful if you could take a few minutes of your time to answer a few questions.


A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

Status: Active printPrint Results Email Results Save Results
Cancer Type: Non-Hodgkin Lymphoma NCT ID: NCT01799889
Trial Phases: Phase II Protocol IDs: GS-US-339-0102 (primary)
Eligibility: 18 and over, Male and Female Study Type: Biomarker/Laboratory analysis
Study Sponsor: Gilead Sciences
NCI Full Details:


This study is to evaluate the efficacy, safety, tolerability, and pharmacodynamics of GS-9973. Up to 200 participants will be enrolled who have one of the following hematological tumor types: relapsed or refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or non-FL indolent non-Hodgkin lymphomas (iNHL; including lymphoplasmacytoid lymphoma/ Waldenström macroglobulinemia [LPL/WM], small lymphocytic lymphoma [SLL], or marginal zone lymphoma [MZL]). If GS-9973 demonstrates promising activity additional participants may be enrolled to evaluate GS-9973 at lower doses, to a maximum of 80 additional participants.

Georgia Cancer Info
Copyright 2014, Georgia Center for Oncology Research and Education, Inc. All Rights Reserved.
Website Designed by Peachtree Solutions

Privacy and Site Use Policies